Related coverage linked through entity extraction aliases.
Aug 24, 2026
New noninvasive biomarkers are advancing early detection of fibrosis. A FAP-Index blood test reduces uncertain liver fibrosis results by up to 70%, a urine-based molecular imaging test detects kidney fibrosis with 84% sensitivity and 94% specificity, and liver MRE can track Gaucher disease severity over time.
Jul 16, 2026
Phase 3 MAJESTY trial results show obinutuzumab led to 37% complete remission at 2 years vs 6% with tacrolimus in primary membranous nephropathy, with comparable safety. Genentech announced the positive data in February 2026, positioning obinutuzumab as a potential first approved therapy for PMN.
Apr 18, 2026
A multicenter retrospective cohort study of 17 patients with type 2 diabetes and end-stage renal disease found injectable semaglutide was associated with descriptive changes in glycemic control and body weight. No cardiovascular deaths, nonfatal myocardial infarctions, or nonfatal strokes were observed during follow-up.
Mar 18, 2026
The FDA is set to make decisions on four drug applications in April 2026, including Orca-T for hematological malignancies, orforglipron for obesity, sparsentan for kidney disease, and a doravirine/islatravir combination for HIV-1.
Feb 18, 2026
The FDA has approved pitolisant tablets for treating cataplexy in pediatric patients aged 6 and older with narcolepsy, making it the only non-scheduled therapy approved for both pediatric and adult narcolepsy patients with or without cataplexy.
